

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/511,549
Confirmation Number	9316
Filing Date	October 18, 2004
First Named Inventor	Takahide OHISHI
Art Unit	1657
Examiner Name	Clark D. PETERSEN
Attorney Docket Number	Q102803

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
CDP	1	US Application No. 11/657,110			CHEN et al.
CDP	2	US 2003/0017528	A1	01-23-2003	CHEN et al.
CDP	3	US 6,468,756		10-22-2002	BONINI et al.
CDP	4	US 2003/0139590	A1	07-24-2003	BONINI et al.
CDP	5	US 7,108,991	A1	09-19-2006	CHEN et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
CDP	6	GB	953,899		04-02-1964	ROLF LAPPE et al.	
CDP	7	EP	0 608 511	A2	08-03-1994	BARBARA ARENA et al.	
CDP	8	WO	87/01257	A2	03-12-0987	PAUL MUNDER	
CDP	9	WO	00/44382		08-03-2000	BEYER et al.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
CDP	10	Communication enclosing a Supplementary Partial European Search Report for EPO Application No. EP 01998193, mailed March 11, 2005 (7 pages).	
	11	ATTWOOD, "The Babel of Bioinformatics", Science, 2000, 290: 471-473	
	12	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, 1990, 247: 1306-1310	
	13	BURGESS et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acid Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue", J. Cell. Biol., 1990, 111: 2129-2138	
	14	KUNTZ, "Structure-Based Strategies for Drug Design and Discovery", Science, 1992, 257: 1078-1082	
	15	LAZAR et al., "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", Mol. Cell. Biol., 1998, 8: 1247-1252	
	16	METZLER et al., "Solution Structure of Human CTLA-4 and delineation of a CD80/CD86 Binding Site Conserved in CD28", Nature Structural Biol., 1997, 4: 527-531	
	17	HOLZ et al., "cAMP-dependent Mobilization of Intracellular Ca <sup>2+</sup> Stores by Activation of Ryanodine Receptors in Pancreatic $\beta$ -Cells", J. Biological Chemistry, 247(20): 14147-14156 (1999)	
	18	Supplementary Partial European Search Report for EPO Application No. EP 01998193, mailed January 3, 2005	


Examiner Signature

Date Considered

10/23/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.



Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/511,549
Confirmation Number	9316
Filing Date	October 18, 2004
First Named Inventor	Takahide OHISHI
Art Unit	1657
Examiner Name	Clark D. PETERSEN
Attorney Docket Number	Q102803

Sheet 2 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
Cor	19	MILLER et al., "Ligand binding to Proteins: The Binding Landscape Model", Protein Science, 1997, 6: 2166-2179	
	20	RUDINGER, "1. Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence", From Peptide Hormones (ed. J. A. Parsons, M.A., B.M., B.Ch.), University Park Press, Baltimore, June 1976, pp. 1-7.	
	21	SKOLNICK et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotech, 2000, 18(1): 34-39	
	22	MESSER W.S. "Vasopressin and Oxytocin" [online], April 3, 2000 [retrieved on 2006-12-19]. Retrieved from the Internet:<URL:http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm>	
	23	Restriction/Election Requirement dated November 1, 2006 in U.S. Application Serial No. 10/975,367	
	24	Response to Restriction Requirement filed on November 30, 2006 in U.S. Application Serial No. 10/975,367	
	25	Non-Final Office Action dated February 7, 2007 in U.S. Application Serial No. 10/975,367	
	26	Amendment as filed May 7, 2007 in response to Non-Final Office Action dated 2/7/2007 in U.S. Application Serial No. 10/975,367	
V	27	Declaration of Patent Interference No. 105,561 [US Application 10/278,437 v. US Patent 7,108,991 and US Application 11/657,110]	

Examiner Signature	Chab. S. P. [Signature]	Date Considered	10/23/2007
--------------------	-------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.